Prosecution Insights
Last updated: November 20, 2026
Application No. 17/607,678

LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE

Final Rejection §102§112
Filed
Oct 29, 2021
Priority
May 02, 2019 — RE 10-2019-0051618 +2 more
Examiner
CANELLA, KAREN A
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Legochem Biosciences Inc.
OA Round
2 (Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
712 granted / 1143 resolved
+2.3% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
53 currently pending
Career history
1203
Total Applications
across all art units

Statute-Specific Performance

§101
6.7%
-33.3% vs TC avg
§103
24.2%
-15.8% vs TC avg
§102
16.6%
-23.4% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1143 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 3, 5, and 15 have been canceled. Claims 1, 9, 14, 16, 18, 20-22, 25, 31-34, 40-42, 47, 48, 49, 51, 52, and 56 have been amended. Claims 1, 2, 9, 10, 14, 16,18, 20-22, 25, 31-34, 40-54, and 56-61 are pending and under consideration. The rejection of claims 9, 10, 42, 47, 48, and 56 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is withdrawn in light of applicant’s amendments. Claim 56 is objected to because of the following informalities: the obvious drawing error in PNG media_image1.png 540 477 media_image1.png Greyscale The structure as drawn has two methylene groups instead of one. The second methylene would interfere with the release of the active agent from the ester, and the structure as written is not supported by the instant specification which provides for the base structure with one methylene: PNG media_image2.png 399 404 media_image2.png Greyscale . Appropriate correction is required. The rejection of claims 1, 2, 9, 10, 14, 16,18, 20-22, 25, 31-34, 40-54, and 57-61 are under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is maintained for reasons of record. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Section 2163 of the M.P.E.P. states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. A “representative number of species” means that the species which are adequately described are representative of the entire genus. See, e.g., AbbVie Deutschland GMBH v. Janssen Biotech, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014). Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus to provide a “representative number” of species. The “structural features common to the members of the genus” needed for one of skill in the art to ‘visualize or recognize’ the members of the genus takes into account the state of the art at the time of the invention. The instant claims are reliant on a genus of linkers, or ligand-drug conjugates comprising the genus of linkers, wherein the genus is highly variant. It is noted that the linkers of “species A” which excludes “species B” requiring that the BL are attached to methylene of a quaternary carbon, are not described in the art and not described in the specification. The instant specification described solely the “species B” linkers, Further both species A and B linkers are highly variant requiring only a tris structure as part of the linker which in the case of species “A” defines only a quaternary or tertiary carbon attached to a NH group. The claims encompass polyalkylene glycol units, maleimide units, substituted or unsubstituted alkylene having 1 to 100 carbons with double or triple bonds, heteroarylenes, substitution of the alkylene with one or more heteroatoms, further substitution of the alkylene with one or more alkyls having 1 to 20 carbons (claim 9), generic amines, generic tertiary amides or quaternary carbons and one or more generic amino acids (claim 10); branching units comprising one or more generic amino acids, one or more hydrogen atoms or alkenes having 1-100 carbon atoms or the functional groups of -C(O)-, -C(O)NR'-, -C(O)O-, -S(O)2NR'-, -P(O)R"NR'-, -S(O)NR'-, or -PO2NR'-, where R' and R" each independently include hydrogen, (C1-C8)alkyl, (C3-C8)cycloalkyl, (Ci-C8)alkoxy, (Ci-C8)alkylthio, mono- or di-(C1-C8)alkylamino, (C3-C20)heteroaryl, or (C6-C20)aryl; or a structure represented by Chemical Formulas 1B to 8B, an oxime or an O-substituted oxime or structures 9B or 10B; the linker further comprising a wherein the connection unit is represented by -(CH2)r(V(CH2)p)q-((CH2)pV)q, (CH2)r(V(CH2)p)gY-, -((CH2)pV)q(CH2)r-, -Y((CH2)pV)q or -(CH2)r(V(CH2)p)gYCH2-, where r is an integer from 0 to 10; p is an integer from 1 to 10; q is an integer from 1 to 20; and V and Y are each independently a single bond, -0-, -5-, -NR21-, -C(O)NR22-, -NR23C(O)-, -NR24SO2-, or - SO2NR25-, where R21 to R2s are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkyl(C6-C2o)aryl, or (C1-C6)alkyl(C3-C2o)heteroaryl; and wherein the binding unit is formed by a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alder reaction, a nucleophilic substitution reaction, a non-aldol type carbonyl reaction, addition to a carbon- carbon multiple bond, an oxidation reaction, or a click reaction; or is formed by a reaction of acetylene with azide or a reaction of an aldehyde or a ketone group with hydrazine or an alkoxyamine; or has a structure represented by any one of the following Chemical Formulas 1D to 4D. Thus, the genus of linkers is highly variant requiring only a minimum of structure. Applicant has reduced to practice the linkers of PNG media_image3.png 222 305 media_image3.png Greyscale PNG media_image4.png 240 311 media_image4.png Greyscale PNG media_image5.png 242 270 media_image5.png Greyscale PNG media_image6.png 191 323 media_image6.png Greyscale PNG media_image7.png 214 383 media_image7.png Greyscale PNG media_image8.png 390 402 media_image8.png Greyscale PNG media_image9.png 261 242 media_image9.png Greyscale PNG media_image10.png 317 351 media_image10.png Greyscale . These linkers fail to adequately describe the required genus of linkers because the genus encompasses members which differ widely in structure from the described linkers. Claims 1 and 14 state that the first linker and the second linker comprise a branching unit, connection unit or binding unit. The branching unit is described in great generality comprising at least one or more amino acids, or a structure of Formulas 1B, 2B, 3B, 7B or 8B. Formulas 1B indicates only a tertiary nitrogen, wherein three moieties are undefined, Formula 8B indicates only a tris structure, wherein four moieties are undefined. Formula 3B and 7B are amides with three moieties undefined. Formula 3B is a tertiary carbon linking amides or a tertiary nitrogen. The branching unit is further defined as comprising (claim 20) PNG media_image11.png 127 582 media_image11.png Greyscale and including (claim 25): at PNG media_image12.png 124 578 media_image12.png Greyscale The binding unit is minimally described as a triazole in formula 1D, 2D and 3D and a minimally escribed as a methanimine in Formula 4D. The connection unit is described as encompassing a plurality of alternative variables: PNG media_image13.png 167 586 media_image13.png Greyscale The connection unit is further described as comprising 1-12 peg units (claim 33) or (claim 34): PNG media_image14.png 70 578 media_image14.png Greyscale It is noted that in none of these cases, are there any constrains as to the precise location of the further moieties within the linker structure. Each of the “branching unit”, “connection unit” and “binding unit” are alternative embodiments. Thus, the linkers need not have more than one branching, binding and connecting unit. Each of the branching, binding and connecting units can be arranged in different orders relative to each other and relative to the further moieties dictated by claims 20, 25 and 32-34 and connected to each other by any structure. Claim 9 dictates that the “linker” any have at least one PEG unit, at least one maleimide unit, a substituted or unsubstituted alkylene having 1-100 carbon atoms. Claim 10 dictates that the “linker” includes an amine, a tertiary amide, a tertiary carbon and a quaternary carbon or at least one amino acid . Claim 40 states that the “linker” includes an isoprenyl unit. When given the broadest reasonable interpretation, the above substituents required by claims 9, 10 and 40 can be anywhere within the overall ”linker” structure . Thus, the genus of linkers and ligand drug conjugates is highly variant. The specification fails to provide a representative number of species which describe the highly variant genus of linkers and ligand drug conjugates comprising the minimum tris structure, the BL1, BL2, BL3 and SL linkers comprising the minimally described alternative of a branching unit, connection unit or binding unit because the genus is highly variant as discussed above, encompassing structures which differ widely from the structures reduced to practice. One of skill in the art would reasonably conclude that applicant was not in possession of the claimed genus of linker and ligand drug conjugates at the time of filing. Applicant argues against the Examiner’s interpretation that the structures reduced to practice do not fall into the genus of having BL attached to the tris structure. This has been considered and found persuasive as applicant argues that the BL are indirectly attached to the TRIS structure. Applicant argues that the unique effects of the linker compound claimed are due to the presence of the Tris structure which allows for the conjugation of two or three active agents without requiring additional branching agents. This has been considered but not found persuasive. There are other linkers known in the art that allow for the conjugation of two or three active agents without additional branching units, such as disclosed by Kim et al (WO2017/089895) in Figure 7B: PNG media_image15.png 112 546 media_image15.png Greyscale and King et al (U.S. 5,824,805) PNG media_image16.png 121 273 media_image16.png Greyscale Applicant argues that the tris structure as claimed herein is a symmetrical structure which provides for a higher purity of the final product in a greater yield. This has been considered but not found persuasive as directed to the written description requirement for the genus of linkers and ligand drug conjugates claimed. The rejection of claims 1, 2, 9. 10, 14, 16, 20-22, 25, 31-34, 53, 54, 58, 60 under 35 U.S.C. 102(a)(1) as being anticipated by Quiles et al (Journal of Medicinal Chemistry, 2010, vol. 53, pp. 586-594) as evidenced by Stagi et al (Spectrochimica Acta, Part A, Molecular and Biomolecular Spectroscopy, 2022, Vol. 283, article no. 121717) is withdrawn in light of applicant’s argument that the corresponding chains to BL1, BL2 and BL3 are not linked to an active agent according to the instant amended claim 1. The rejection of claims 1, 2, 9, 10, 14, 16, 18, 21, 31-34, 43, 47-51, 53, 54, 58-61 under 35 U.S.C. 102(a)(1) as being anticipated by Lyon et al (WO2015/057699) is withdrawn in light of applicant’s argument that the corresponding chains to BL1, BL2 and BL3 are not linked to an active agent according to the instant amended claim 1. Claims 1, 2, 9, 10, 14, 16,18, 20-22, 25, 31-34, 40-54, and 57-61 are rejected. Claim 56 is objected to for a drawing error and being dependent on a rejected claim THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAREN A CANELLA whose telephone number is (571)272-0828. The examiner can normally be reached M-F 10-6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. KAREN A. CANELLA Examiner Art Unit 1643 /Karen A. Canella/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Oct 29, 2021
Application Filed
May 12, 2026
Non-Final Rejection mailed — §102, §112
Aug 12, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779044
PLATELET-FACILITATED DELIVERY OF THERAPEUTIC COMPOUNDS
4y 9m to grant Granted Nov 03, 2026
Patent 12780901
NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF
3y 6m to grant Granted Nov 03, 2026
Patent 12760275
GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF
2y 1m to grant Granted Oct 13, 2026
Patent 12753393
LIQUID CRYSTAL SCAFFOLDS AND USE THEREOF FOR ORGANOID, SPHEROID, AND 3D CELLAGGREGATE MANUFACTURING
1y 3m to grant Granted Oct 06, 2026
Patent 12747250
CAMPTOTHECIN DERIVATIVES
4y 11m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
95%
With Interview (+32.8%)
3y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1143 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month